Two new drug candidates for ADPKD have appeared on ClinicalTrials.gov since our last pipeline sweep, bringing the number of drugs we track to 21.
GV-100 (NCT07788014), from Gilva Therapeutics, is an oral drug developed for ADPKD. Its first-in-human study began in June 2026 at CMAX Clinical Research in Adelaide, Australia, and is enrolling 80 healthy volunteers. The randomized, double-blind, placebo-controlled study has four parts: single and multiple ascending doses, a food-effect arm and a drug-drug interaction arm. Results are expected by March 2027, after which a study in ADPKD patients would be the logical next step.
GBP-213 (NCT07891364) is a subcutaneous injection being tested directly in ADPKD patients. The early Phase 1 study at RenJi Hospital, Shanghai Jiao Tong University School of Medicine, is expected to start in November 2026. It will enroll 24 adults aged 18–65 with rapidly progressive ADPKD and eGFR between 30 and 100, across three dose-escalation levels and an expansion cohort. Alongside safety, it will measure pharmacodynamics and preliminary efficacy.
Neither sponsor has published the drug's target or mechanism. We will update both entries as details emerge, typically through a conference abstract or company announcement.